IMF Videos Search Content For Healthcare Professional (122) Healthcare Provider (122) Care Partner (75) Patient (74) Series - Any - ASCO/EHA (49) ASH (60) Ask Dr. Durie (16) Black Swan Research Initiative (5) Community Workshops (4) Emerging Therapies (6) Facebook Live (10) Health Equity (2) IMWG (3) Inspirational (3) Living Well with Myeloma (4) Myeloma in a Minute (1) Myeloma Made Simple (3) Patient & Family Webinar (4) Q&A (7) Recent News and Developments (4) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (65) High-Risk Myeloma (42) High-risk Smoldering Myeloma (34) Late Relapse (4–6 Lines of Therapy) (81) MGUS (35) Newly Diagnosed (Pre-Treatment or First Treatment) (64) Smoldering Myeloma (50) Types of Therapy Immunomodulatory drugs (IMiDs) (58) Immunotherapies (CAR T; BiTE, etc.) (93) Monoclonal antibodies (48) Proteasome inhibitors (43) Stem cell transplant (40) Steroids (41) Supportive Care (36) Year Published 2026 (16) 2025 (38) 2024 (58) 2023 (39) 2022 (10) 2021 (7) 2020 (1) 2019 (9) 2018 (2) 2017 (1) 2016 (3) Trusted Voices Dr. Joseph Mikhael (36) Dr. Brian GM Durie (15) Dr. María-Victoria Mateos (6) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (5) Dr. Saad Usmani (3) Dr. Sigurður Kristinsson (3) Dr. Shaji Kumar (2) Dr. Urvi A. Shah (2) Dr. Sagar Lonial (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Updated results from iMMagine-1: Phase 2 study of anitocabtagene autoleucel for relapsed/refractory multiple myeloma July 18, 2025 ASCO/EHA Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone in NDMM: MRD Negativity Rates and Safety July 17, 2025 ASCO/EHA Long-term Outcomes of Cilta-cel in Relapsed/Refractory Multiple Myeloma July 17, 2025 ASCO/EHA Top 10 Myeloma Breakthroughs from ASCO & EHA: Frontline Therapy, Early & Late Relapse, and CAR T-cell Insights July 17, 2025 Emerging Therapies Multiple Myeloma Q&A: Why Diagnosis Can Take 12+ Months, MGUS, Costs & FDA News July 10, 2025 Q&A Top Myeloma Research Presented at ASCO, EHA & IMWG 2025 Webinar: The Patient Perspective July 1, 2025 ASCO/EHA Elranatamab in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: MagnetisMM-6 June 27, 2025 ASCO/EHA CAR-T Therapy in RR AL Amyloidosis: NEXICART-2 Trial Safety and Efficacy June 23, 2025 ASCO/EHA First-in-human JNJ-79635322 trispecific antibody study in RRMM patients: Initial phase 1 results June 19, 2025 ASCO/EHA Why 4 Drugs Work Better in Myeloma: Quadruplet Therapy Explained | Myeloma Made Simple June 19, 2025 Myeloma Made Simple IMWG Conference Series 2025: Making Sense of Treatment June 17, 2025 IMWG MMR Vaccine Safety & CAR‑T Eligibility, and More: Top 10 Myeloma Patient Q&A May 8, 2025 Q&A Load More
